Abstract
Alongside the prescription of commonly used antivirals, such as acyclovir, remdesivir, oseltamivir, and ciprofloxacin, the most efficient way to prevent or treat communicable diseases is by vaccination. Vaccines have been the most efficient way to prevent or treat highly transmissible infectious agents, such as Ebola, Anthrax, and Dengue Fever. Most epidemics of these highly transmissible infectious agents occur in places, such as South America, Central America, Tropical Asia, and Africa, where the availability of resources and access to adequate healthcare are limited. However, recent events in history have proven that even with access to resources and proper healthcare, those in firstworld countries are not invincible when it comes to infectious diseases and epidemics. The Ebola virus outbreak in West Africa highlighted the gaps in therapeutic advancement and readiness and led to the rapid development of novel vaccine approaches. Viral vectors, in the case of the Ebola vaccine the Vesicular Stomatitis Virus (VSV), can be safely used to activate or initiate the innate adaptive immune response to protect against viral infection. When developed properly and with extensive study, novel vaccine approaches allow physicians and health experts to control the rate at which viruses spread or prevent transmission. This review will discuss the advantages of viral vector vaccines, their chemistry and development, and the pathophysiology of the Ebola virus to develop advantageous and efficacious treatments.
Graphical Abstract
[http://dx.doi.org/10.21037/atm-20-3312] [PMID: 32566565]
[http://dx.doi.org/10.1016/j.onehlt.2022.100379] [PMID: 35313715]
[http://dx.doi.org/10.15585/mmwr.mm6850a3] [PMID: 31856146]
[http://dx.doi.org/10.1016/S0140-6736(18)33132-5] [PMID: 30777297]
[http://dx.doi.org/10.1056/NEJMoa1910993] [PMID: 31774950]
[http://dx.doi.org/10.1371/journal.pmed.1001967] [PMID: 26930627]
[http://dx.doi.org/10.1371/journal.pmed.1002535] [PMID: 29584730]
[http://dx.doi.org/10.3390/v11040326] [PMID: 30987343]
[http://dx.doi.org/10.1016/j.jaut.2019.102375] [PMID: 31806422]
[http://dx.doi.org/10.1016/S0140-6736(19)30036-4] [PMID: 30686586]
[http://dx.doi.org/10.1056/NEJMoa1604330] [PMID: 27732819]
[http://dx.doi.org/10.1056/NEJMoa1614067] [PMID: 29020589]
[http://dx.doi.org/10.1093/infdis/jiy698] [PMID: 30561672]
[http://dx.doi.org/10.1038/nrd.2017.251] [PMID: 29375139]
[http://dx.doi.org/10.1002/adhm.201600739] [PMID: 27990771]
[http://dx.doi.org/10.3390/v13122441] [PMID: 34960709]
[http://dx.doi.org/10.3390/v14010142] [PMID: 35062347]
[http://dx.doi.org/10.1093/infdis/jiab552] [PMID: 34791300]
[http://dx.doi.org/10.1016/j.cell.2020.10.002] [PMID: 33159858]
[http://dx.doi.org/10.1016/j.celrep.2020.01.026] [PMID: 32049004]
[http://dx.doi.org/10.1111/cts.13383] [PMID: 35895082]
[http://dx.doi.org/10.3201/eid2311.170171] [PMID: 29047428]
[http://dx.doi.org/10.3390/v11070647] [PMID: 31311112]
[http://dx.doi.org/10.1126/scitranslmed.abd9696] [PMID: 33827978]
[http://dx.doi.org/10.2217/fvl.09.56] [PMID: 20198110]
[http://dx.doi.org/10.1016/j.bbrc.2011.02.110] [PMID: 21362405]
[http://dx.doi.org/10.3390/pathogens10101330] [PMID: 34684279]
[http://dx.doi.org/10.1016/j.cellimm.2017.11.009] [PMID: 29195741]
[http://dx.doi.org/10.1371/journal.ppat.1004509] [PMID: 25412102]
[http://dx.doi.org/10.1006/viro.1994.1147] [PMID: 8122375]
[http://dx.doi.org/10.1038/s41586-022-05271-2] [PMID: 36171293]
[http://dx.doi.org/10.2174/1389557522666220404085858] [PMID: 35379146]
[http://dx.doi.org/10.1172/jci.insight.137260] [PMID: 32434986]
[http://dx.doi.org/10.1016/j.celrep.2022.111562] [PMID: 36288690]
[http://dx.doi.org/10.1016/j.antiviral.2021.105226] [PMID: 34923028]
[http://dx.doi.org/10.3390/v11040373] [PMID: 31018522]
[http://dx.doi.org/10.3390/v7102892] [PMID: 26512687]
[http://dx.doi.org/10.3390/vaccines10091446] [PMID: 36146524]
[http://dx.doi.org/10.1073/pnas.1414991111] [PMID: 25385608]
[http://dx.doi.org/10.3389/fncir.2013.00011] [PMID: 23403489]
[http://dx.doi.org/10.3390/pathogens10091092] [PMID: 34578125]
[http://dx.doi.org/10.1128/JVI.02598-15] [PMID: 26676789]
[http://dx.doi.org/10.1038/scientificamerican0315-48]
[http://dx.doi.org/10.1128/JVI.78.10.5458-5465.2004] [PMID: 15113924]
[http://dx.doi.org/10.1016/j.xpro.2020.100209] [PMID: 33377103]
[http://dx.doi.org/10.1086/514291] [PMID: 9988181]
[http://dx.doi.org/10.1016/j.mex.2020.100806] [PMID: 32195130]
[http://dx.doi.org/10.1016/j.jbiotec.2020.01.015] [PMID: 32006630]
[http://dx.doi.org/10.1016/j.molmed.2004.03.003] [PMID: 15121047]
[http://dx.doi.org/10.1016/S1473-3099(21)00125-0] [PMID: 34529963]
[http://dx.doi.org/10.1172/JCI132438] [PMID: 32315287]
[http://dx.doi.org/10.1016/j.vaccine.2023.01.059] [PMID: 36725433]
[http://dx.doi.org/10.1016/S1473-3099(20)30476-X] [PMID: 33217361]
[http://dx.doi.org/10.1016/S1473-3099(21)00128-6] [PMID: 34529962]
[http://dx.doi.org/10.1016/S2666-5247(21)00235-4] [PMID: 35544042]
[http://dx.doi.org/10.1016/S1473-3099(15)00154-1] [PMID: 26248510]
[http://dx.doi.org/10.1038/s41541-020-0179-4] [PMID: 32337075]